Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue

Alzheimer Disease and Associated Disorders

Volumn 26, Issue 1, 2012, Pages 8-16

  Choi, Seok Rye ^a   Schneider, Julie A ^b   Bennett, David A ^b   Beach, Thomas G ^c   Bedell, Barry J ^d,e   Zehntner, Simone P ^d   Krautkramer, Michael J ^a   Kung, Hank F ^a   Skovronsky, Daniel M ^a   Hefti, Franz ^a   Clark, Christopher M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

18F AV 45; A ; A plaque; Alzheimer disease; amyloid PET imaging; autoradiography; florbetapir F 18; PET imaging; postmortem

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; FLORBETAPIR F 18;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIGAND BINDING; MALE; MICROSCOPY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OPTICAL DENSITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; SENILE PLAQUE; SILVER STAINING;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; AUTOPSY; AUTORADIOGRAPHY; BRAIN; ETHYLENE GLYCOLS; HUMANS; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84863230382     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31821300bc     Document Type: Article

References (33)

1. Recommendations to Update Diagnostic Criteria. 2010. Alzheimer's Association. 8-8-0010. http://www.alz.org/research/diagnostic-criteria/ (Accessed 2/24/11).
2. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol. 2007;6:734-746. (Pubitemid 47058377)
3. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-344.
5. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006;314:781-784. (Pubitemid 44706637)
6. The National Institute on Aging aRIWGoDCftNAoAD. Consensus recommendtions for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18:1-2.
7. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598-10606. (Pubitemid 41681907)
8. Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol. 2008;21:683-687.
9. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des. 2004;10:1469-1492. (Pubitemid 38559761)
10. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7: 129-135.
11. Koole M, Lewis DM, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818-822.
12. Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887-1894.
13. Zhang W, Oya S, Kung MP, et al. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005;32:799-809. (Pubitemid 41505313)
14. Zhang W, Kung MP, Oya S, et al. 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol. 2007;34:89-97. (Pubitemid 46038150)
15. Schneidera JA, Aggarwal NT, Barnes L, et al. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18: 691-701.
16. Beach TG, Sue LI, Walker DG, et al. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank. 2008;9:229-245.
17. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease: a primer for practicing pathologists. Arch Pathol Lab Med. 1993;117:132-144. [see comments] (Pubitemid 23057613)
18. Walker LC, Price DL, Voytko ML, et al. Labeling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropath Expl Neurol. 1994;53:377-383. (Pubitemid 24216037)
19. Akiyama H, Mori H, Saido T, et al. Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abetacontaining glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia. 1999;25:324-331. (Pubitemid 29083832)
20. LeVine H III. Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide. Arch Biochem Biophys. 2003;417:112-122.
21. Grundke-Iqbal I, Iqbal K, George L, et al. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:2853-2857. (Pubitemid 19112638)
22. Wisniewski HM, Wen GY, Kim KS. Comparison of four staining methods on the detection of neuritic plaques. Acta Neuropathol. 1989;78:22-27. (Pubitemid 19150891)
23. Zehntner SP, Chakravarty MM, Bolovan RJ, et al. Synergistic tissue counterstaining and image segmentation techniques for accurate, quantitative immunohistochemistry. J Histochem Cytochem. 2008;56:873-880.
24. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:10-15.
25. Thompson PW, Ye L, Morgenstern JL, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem. 2009;109:623-630.
26. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131: 6-45.
27. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of betaamyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol. 2008;65:1304-1309.
28. Burack MA, Hartlein J, Flores HP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010;74:77-84.
29. Bharadwaj PR, Dubey AK, Masters CL, et al. Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med. 2009;13:412-421.
30. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333-366. (Pubitemid 44118036)
31. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5-36.
32. Irvine GB, El-Agnaf OM, Shankar GM, et al. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med. 2008;14: 451-464.
33. Look GC, Jerecic J, Cherbavaz DB, et al. Discovery of ADDL-targeting small molecule drugs for Alzheimer's disease. Curr Alzheimer Res. 2007;4:562-567. (Pubitemid 350248392)